Biotechnology Assets (XMAD:BST) EBIT: €-1.46 Mil (TTM As of Dec. 2025)

What is Biotechnology Assets EBIT?

Biotechnology Assets XMAD:BST -4.24% 19 EBIT is €-1.46 Mil as of Dec. 2025. GuruFocus rates XMAD:BST with a GF Score™ of 19/100 and a GF Value™ of €0.30 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biotechnology Assets's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-0.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.46 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biotechnology Assets's annualized ROC % for the quarter that ended in Dec. 2025 was 0.47%. Biotechnology Assets's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -34.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biotechnology Assets's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -7.24%.

Biotechnology Assets (XMAD:BST) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biotechnology Assets's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	0.056 * ( 1 - 0% )	/	( (12.305	+	11.516)	/ 2 )
=	0.056	/	11.9105
=	0.47 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13.458	-	1.102	-	( 0.52	-	max(0, 3.102	-	3.153	+	0.52	))
=	12.305

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13.563	-	1.453	-	( 0.594	-	max(0, 3.27	-	4.591	+	0.594	))
=	11.516

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Biotechnology Assets's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.358	/	( ( (2.264 + max(1.086, 0))	+	(2.204 + max(2.273, 0)) )	/	2 )
=	-1.358	/	( ( 3.35	+	4.477 )	/	2 )
=	-1.358	/	3.9135
=	-34.70 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.273	+	0	+	0.097)	-	(1.102	+	0	+	0.182)
=	1.086

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.757	+	0	+	0.081)	-	(1.453	+	0	+	0.112)
=	2.273

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biotechnology Assets's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-1.462	/	20.188
	=	-7.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets EBIT Related Terms

Biotechnology Assets EBIT Historical Data

* Premium members only.

The historical data trend for Biotechnology Assets's EBIT can be seen below:

Biotechnology Assets EBIT Chart

Biotechnology Assets Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-2.06

-1.70

2.63

-2.88

-1.46

Biotechnology Assets Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-0.44	-1.60	-1.27	-0.78	-0.68

XMAD:BST vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Biotechnology Assets's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotechnology Assets EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's EV-to-EBIT falls into.

Save Embed

19GF Score

Biotechnology Assets SA XMAD:BST

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biotechnology Assets EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.46 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-1.46 Mil mean?

Biotechnology Assets (XMAD:BST) has a EBIT of €-1.46 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biotechnology Assets.

Is Biotechnology Assets' EBIT too high?

Biotechnology Assets' current EBIT is €-1.46 Mil. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Biotechnology Assets' EBIT compare to VRTX and REGN?

Biotechnology Assets' EBIT of €-1.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biotechnology Assets. Biotechnology Assets's current EBIT is €-1.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biotechnology Assets stock overvalued right now?

Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 24.7% below its estimated fair value. The current EBIT is €-1.46 Mil. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current EBIT is €-1.46 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Modestly Undervalued.

Key valuation signals for XMAD:BST:

EBIT: €-1.46 Mil
GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Industry Healthcare Biotechnology

Comparable Companies VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM ROIV INCY MRNA HKSE:01801 HKSE:02269 OCSE:GMAB JAZZ

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591

Website https://www.biatgroup.com

Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.

19GF Score

Get the complete analysis for XMAD:BST

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23

Price

€0.30

GF Value

View XMAD:BST Analysis

See EBIT data for all stocks →